Business
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINAT
About this update from Sagimet Biosciences Inc. - Series A
[{"type":"image","alt":"Sagimet Biosciences Inc.","displaySize":"","headline":null,"caption":"Sagimet Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AmJDa7oTdvowtNmgiL7OTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25","width":300,"height":110}},"lazy":false},{"type":"text","content":"SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat.","length":591,"tagName":"p"},{"type":"text","content":"MASH-TAG 2026 Poster Presentation Details:","length":42,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Denifanstat elicited a significant ≥2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial","length":216,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Presenting Author:","length":18,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Rohit Loomba, M.D., M.H.Sc., University of California San Diego","length":73,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;",...